Eclipse Life Sciences

Executive Summary

Eclipse Life Sciences is a private contract development and manufacturing organization (CDMO) headquartered in Durham, North Carolina, founded in 2019. The company specializes in sterile injectable pharmaceuticals, offering end-to-end services from formulation development to commercial-scale aseptic fill-finish. Its focus on biosimilars and small molecule drugs positions it within a growing segment of the pharmaceutical outsourcing market, driven by increasing demand for complex generics and biologics. Although Eclipse operates in a competitive landscape, its niche in sterile injectables and early-stage capabilities may allow it to capture opportunities from large pharma seeking flexible CDMO partners. The company's lack of disclosed funding or revenue suggests it is still in the growth phase, likely relying on customer contracts and private investment to scale operations. Given the limited public information, the company's potential hinges on its ability to secure new clients, expand capacity, and navigate regulatory requirements.

Upcoming Catalysts (preview)

• Q3 2026Announcement of new client partnership or manufacturing contract40% success
• Q4 2026Completion of facility expansion or capacity addition30% success
• Q2 2027Regulatory approval or inspection milestone25% success